Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide: What It Is and How It's Being Studied for Weight Loss Cagrilintide Disguised Alpha CAGRILINTIDE 5MG Oneday Compounds Novo Nordisk files for FDA approval of CagriSema, the first once weekly combination of GLP1 and amylin analogues for weight management